Apparent changes in the epidemiology and severity of multiple sclerosis

被引:101
作者
Koch-Henriksen, Nils [1 ,2 ]
Magyari, Melinda [2 ,3 ]
机构
[1] Aarhus Univ Hosp, Dept Clin Epidemiol, Aarhus, Denmark
[2] Copenhagen Univ Hosp, Danish Multiple Sclerosis Registry, Copenhagen, Denmark
[3] Copenhagen Univ Hosp, Dept Neurol, Danish Multiple Sclerosis Ctr, Copenhagen, Denmark
关键词
LONG-TERM DISABILITY; WILL ROGERS PHENOMENON; NATURAL-HISTORY; DIAGNOSTIC-CRITERIA; BRITISH-COLUMBIA; INCREASING PREVALENCE; PROGNOSTIC-FACTORS; EXCESS MORTALITY; TEMPORAL TRENDS; RISK-FACTOR;
D O I
10.1038/s41582-021-00556-y
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Multiple sclerosis (MS) is an immunological disease that causes acute inflammatory lesions and chronic inflammation in the CNS, leading to tissue damage and disability. As awareness of MS has increased and options for therapy have come into use, a large amount of epidemiological data have been collected, enabling studies of changes in incidence and disease course over time. Overall, these data seem to indicate that the incidence of MS has increased, but the course of the disease has become milder, particularly in the 25 years since the first disease-modifying therapies (DMTs) became available. A clear understanding of these trends and the reasons for them is important for understanding the factors that influence the development and progression of MS, and for clinical management with respect to prevention and treatment decisions. In this Review, we consider the evidence for changes in the epidemiology of MS, focusing on trends in the incidence of the disease over time and trends in the disease severity. In addition, we discuss the factors influencing these trends, including refinement of diagnostic criteria and improvements in health-care systems that have increased diagnosis in people with mild disease, and the introduction and improvement of DMT. In this Review, Koch-Henriksen and Magyari consider the evidence for changes in the epidemiology of multiple sclerosis, focusing on trends in the incidence of the disease over time and trends in the disease severity, and discuss the factors influencing these trends.
引用
收藏
页码:676 / 688
页数:13
相关论文
共 150 条
  • [31] Prognostic indicators for long-term disability in multiple sclerosis patients
    Damasceno, Alfredo
    Von Glehn, Felipe
    Brandao, Carlos Otavio
    Damasceno, Benito Pereira
    Cendes, Fernando
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2013, 324 (1-2) : 29 - 33
  • [32] Application of the 2017 Revised McDonald Criteria for Multiple Sclerosis to Patients With a Typical Clinically Isolated Syndrome
    de Vries, Roos M. van der Vuurst
    Mescheriakova, Julia Y.
    Wong, Yu Yi M.
    Runia, Tessel F.
    Jafari, Naghmeh
    Samijn, Johnny P.
    de Beukelaar, Janet W. K.
    Wokke, Beatrijs H. A.
    Siepman, Theodora A. M.
    Hintzen, Rogier Q.
    [J]. JAMA NEUROLOGY, 2018, 75 (11) : 1392 - 1398
  • [33] Increasing incidence of multiple sclerosis among women in Lorraine, Eastern France
    Debouverie, M.
    Pittion-Vouyovitch, S.
    Louis, S.
    Roederer, T.
    Guillemin, F.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2007, 13 (08) : 962 - 967
  • [34] Smoking and multiple sclerosis: A systematic review and meta-analysis using the Bradford Hill criteria for causation
    Degelman, Michelle L.
    Herman, Katya M.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 17 : 207 - 216
  • [35] INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    DUQUETTE, P
    GIRARD, M
    DESPAULT, L
    DUBOIS, R
    KNOBLER, RL
    LUBLIN, FD
    KELLEY, L
    FRANCIS, GS
    LAPIERRE, Y
    ANTEL, J
    FREEDMAN, M
    HUM, S
    GREENSTEIN, JI
    MISHRA, B
    MULDOON, J
    WHITAKER, JN
    EVANS, BK
    LAYTON, B
    SIBLEY, WA
    LAGUNA, J
    KRIKAWA, J
    PATY, DW
    OGER, JJ
    KASTRUKOFF, LF
    MOORE, GRW
    HASHIMOTO, SA
    MORRISON, W
    NELSON, J
    GOODIN, DS
    MASSA, SM
    GUTTERIDGE, E
    ARNASON, BGW
    NORONHA, A
    REDER, AT
    MARTIA, R
    EBERS, GC
    RICE, GPA
    LESAUX, J
    JOHNSON, KP
    PANITCH, HS
    BEVER, CT
    CONWAY, K
    WALLENBERG, JC
    BEDELL, L
    VANDENNOORT, S
    WEINSHENKER, B
    WEISS, W
    REINGOLD, S
    PACHNER, A
    TAYLOR, W
    [J]. NEUROLOGY, 1993, 43 (04) : 655 - 661
  • [36] A 20-Year Incidence Trend (1989-2008) and Point Prevalence (March 20, 2009) of Multiple Sclerosis in Tehran, Iran: A Population-Based Study
    Elhami, Seyedeh-Robab
    Mohammad, Kazem
    Sahraian, Mohammad Ali
    Eftekhar, Hassan
    [J]. NEUROEPIDEMIOLOGY, 2011, 36 (03) : 141 - 147
  • [37] Is benign MS really benign? What a meaningful classification beyond the EDSS must take into consideration
    Ellenberger, David
    Flachenecker, Peter
    Haas, Judith
    Hellwig, Kerstin
    Paul, Friedemann
    Stahmann, Alexander
    Warnke, Clemens
    Zettl, Uwe K.
    Rommer, Paulus S.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 46
  • [38] Eskandarieh S, 2017, IRAN J PUBLIC HEALTH, V46, P699
  • [39] Incidence and prevalence of multiple sclerosis in persian gulf area: A systematic review and meta-analysis
    Etemadifar, Masoud
    Nikanpour, Yalda
    Neshatfar, Amir
    Mansourian, Marjan
    Fitzgerald, Sean
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 40
  • [40] Estimated Prevalence and Incidence of Multiple Sclerosis in Iran
    Etemadifar, Masoud
    Izadi, Sadegh
    Nikseresht, Alireza
    Sharifian, Maryam
    Sahraian, Mohammad Ali
    Nasr, Zahra
    [J]. EUROPEAN NEUROLOGY, 2014, 72 (5-6) : 370 - 374